Actualités Numinus Wellness Inc - NUMI | Actions Toronto Stock Exchange

Discussions et idées de trading en temps réel : négociez en toute confiance avec notre puissante plateforme.

Premium

Numinus to Host Q2 Fiscal 2024 Results Conference Call on April 15, 2024

Numinus to Host Q2 Fiscal 2024 Results Conference Call on April 15, 2024 PR Newswire VANCOUVER, BC, April 9...

Numinus Wellness Submits Clinical Trial Application

Numinus Wellness Submits Clinical Trial Application PR Newswire VANCOUVER, BC, March 20, 2024 VANCOUVER, BC...

Numinus Wellness Provides Corporate Update

Numinus Wellness Provides Corporate Update PR Newswire VANCOUVER, BC, March 12, 2024 Announces Date of Annual...

Numinus Wellness Congratulates MindMed on Positive Results from Phase 2B Clinical Trials of MM120 for Generalized Anxiety Disorder

Numinus Wellness Congratulates MindMed on Positive Results from Phase 2B Clinical Trials of MM120 for...

/C O R R E C T I O N from Source -- Numinus Wellness Inc./

/C O R R E C T I O N from Source -- Numinus Wellness Inc./ PR Newswire VANCOUVER, BC, Feb. 1, 2024 In the news...

Numinus Wellness Divests of Holdings in Alto Neuroscience Inc.

Numinus Wellness Divests of Holdings in Alto Neuroscience Inc. PR Newswire VANCOUVER, BC, Feb. 1, 2024 This...

Numinus Wellness Inc. Announces First Quarter Fiscal 2024 Results

Numinus Wellness Inc. Announces First Quarter Fiscal 2024 Results PR Newswire VANCOUVER, BC, Jan. 15, 2024 Q1...

Numinus to Host Q1 Fiscal 2024 Results Conference Call on January 15, 2024

Numinus to Host Q1 Fiscal 2024 Results Conference Call on January 15, 2024 PR Newswire VANCOUVER, BC, Jan. 2, 2024 VANCOUVER, BC, Jan. 2, 2024...

Cedar Clinical Research selected as clinical research site for Beckley Psytech's Phase 2b Study

Cedar Clinical Research selected as clinical research site for Beckley Psytech's Phase 2b Study PR...

Numinus Congratulates MAPS on its Application to the FDA for MDMA-Assisted Therapy for PTSD

Numinus Congratulates MAPS on its Application to the FDA for MDMA-Assisted Therapy for PTSD PR...

Numinus Wellness Inc. Announces Fourth Quarter and Full Year Fiscal 2023 Results

Numinus Wellness Inc. Announces Fourth Quarter and Full Year Fiscal 2023 Results PR Newswire VANCOUVER, BC...

Numinus to Host Q4 2023 and Annual Results Conference Call on November 29, 2023

Numinus to Host Q4 2023 and Annual Results Conference Call on November 29, 2023 PR Newswire VANCOUVER, BC, Nov. 21, 2023 VANCOUVER, BC, Nov. 21...

Numinus Announces Psychedelic Program for Mental Distress Associated with Chronic and Serious Illness through Cedar Clinical Research

Numinus Announces Psychedelic Program for Mental Distress Associated with Chronic and Serious Illness through Cedar Clinical Research PR...

Numinus Wellness Inc. Announces At-The-Market Offering Equity Program

Numinus Wellness Inc. Announces At-The-Market Offering Equity Program PR Newswire VANCOUVER, BC, Sept. 25, 2023 VANCOUVER, BC, Sept. 25, 2023...

Numinus Congratulates MAPS on its Phase 3 Study Results Published in Nature Medicine

Numinus Congratulates MAPS on its Phase 3 Study Results Published in Nature Medicine PR Newswire VANCOUVER, BC, Sept. 19, 2023 Study Results are...

Forums

Afficher les forums

Aucune Discussion Trouvée

Ajouter une Discussion

	Prix en temps réel	Carnet d'ordres
BATS Europe
Chi-X Europe
Euronext

	Prix en temps réel	Carnet d'ordres
BATS Europe
Chi-X Europe
Euronext

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Numinus Wellness Inc (NUMI)

Discussions et idées de trading en temps réel : négociez en toute confiance avec notre puissante plateforme.

NUMI Actualités

Numinus to Host Q2 Fiscal 2024 Results Conference Call on April 15, 2024

Numinus Wellness Submits Clinical Trial Application

Numinus Wellness Provides Corporate Update

Numinus Wellness Congratulates MindMed on Positive Results from Phase 2B Clinical Trials of MM120 for Generalized Anxiety Disorder

/C O R R E C T I O N from Source -- Numinus Wellness Inc./

Numinus Wellness Divests of Holdings in Alto Neuroscience Inc.

Numinus Wellness Inc. Announces First Quarter Fiscal 2024 Results

Numinus to Host Q1 Fiscal 2024 Results Conference Call on January 15, 2024

Cedar Clinical Research selected as clinical research site for Beckley Psytech's Phase 2b Study

Numinus Congratulates MAPS on its Application to the FDA for MDMA-Assisted Therapy for PTSD

Numinus Wellness Inc. Announces Fourth Quarter and Full Year Fiscal 2023 Results

Numinus to Host Q4 2023 and Annual Results Conference Call on November 29, 2023

Numinus Announces Psychedelic Program for Mental Distress Associated with Chronic and Serious Illness through Cedar Clinical Research

Numinus Wellness Inc. Announces At-The-Market Offering Equity Program

Numinus Congratulates MAPS on its Phase 3 Study Results Published in Nature Medicine

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Vendredi fou

Jusqu'à 65% de réduction sur Intégral

Cours Euronext Niveau 1 et carnet d'ordres

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Numinus Wellness Inc (NUMI) Actualités

Numinus Wellness Inc (NUMI)

Discussions et idées de trading en temps réel : négociez en toute confiance avec notre puissante plateforme.

NUMI Actualités

Numinus to Host Q2 Fiscal 2024 Results Conference Call on April 15, 2024

Numinus Wellness Submits Clinical Trial Application

Numinus Wellness Provides Corporate Update

Numinus Wellness Congratulates MindMed on Positive Results from Phase 2B Clinical Trials of MM120 for Generalized Anxiety Disorder

/C O R R E C T I O N from Source -- Numinus Wellness Inc./

Numinus Wellness Divests of Holdings in Alto Neuroscience Inc.

Numinus Wellness Inc. Announces First Quarter Fiscal 2024 Results

Numinus to Host Q1 Fiscal 2024 Results Conference Call on January 15, 2024

Cedar Clinical Research selected as clinical research site for Beckley Psytech's Phase 2b Study

Numinus Congratulates MAPS on its Application to the FDA for MDMA-Assisted Therapy for PTSD

Numinus Wellness Inc. Announces Fourth Quarter and Full Year Fiscal 2023 Results

Numinus to Host Q4 2023 and Annual Results Conference Call on November 29, 2023

Numinus Announces Psychedelic Program for Mental Distress Associated with Chronic and Serious Illness through Cedar Clinical Research

Numinus Wellness Inc. Announces At-The-Market Offering Equity Program

Numinus Congratulates MAPS on its Phase 3 Study Results Published in Nature Medicine

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Vendredi fou

Jusqu'à 65% de réduction sur Intégral

Cours Euronext Niveau 1 et carnet d'ordres